Table 1

Potencies of monoamine reuptake blockers in behavioral and biochemical studies

Drug	ED₅₀	Relative Behavioral Potency^1-a		Relative in VitroPotency^1-b		Group^1-c
Drug	ED₅₀	Obtained	Predicted	5-HT	NE	DA	5-HT	NE	DA
	μmol/kg
5-HT/NE
Paroxetine	2.2	0.39	0.49	0.0012	0.40	19	P	M	I
Citalopram	8.1	1.4	1.8	0.0069	40	132	P	I	I
Fluoxetine	11	1.9	1.1	0.027	1.7	16	P	M	I
Alaproclate	14	2.5	3.4	0.34	145	35	S	I	I
Desipramine	2.3	0.39	2.2*	0.81	0.0044	29	S	P	I
Talsupram	12	2.0	3.2	3.3	0.0036	30	M	P	I
Nortriptyline	16	2.8	2.4	2.3	0.035	12	M	P	I
Imipramine	20	3.5	2.1	0.13	0.091	58	S	S	I
Nisoxetine	38	6.6	1.2*	1.4	0.029	1.7	M	P	M
DA/5-HT/NE
Mazindol	1.1	0.20	0.19	0.12	0.0030	0.058	P	P	S
Indatraline	3.7	0.64	0.027*	0.0018	0.0012	0.0032	P	P	P
Nomifensine	5.3	0.93	0.69	3.2	0.030	0.15	M	P	S
Cocaine	5.7	1.0	1.1	1.0	1.0	1.0	S	M	M
Methylphenidate	7.8	1.4	3.2	95	0.74	0.76	I	M	M
GBR-12935	12	2.1	0.26*	0.95	3.2^1-d	0.0077	S	W	S
Cocaethylene	18	3.2	2.0	7.0	3.6	1.1	W	W	M
Bupropion	24	4.2	4.5	73	6.8	1.9	I	I	M
Procaine	317	55	39	1971^1-d	136^1-d	83	I	I	I

↵1-a Behavioral potency relative to cocaine for enhancement of the discriminative stimulus effects of 2.5 mg/kg cocaine.
↵1-b Potencies relative to cocaine were obtained from the literature as described under “Methods.”
↵1-c P = potent; S = strong; M = moderate; W = weak; I = “inactive” based on designations as described byKoe (1976).
↵1-d Relative potencies based on binding results.
* Significant deviation (P < .05) from obtained relative behavioral potency.